Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor

Blocking the activity of the programmed cell death protein 1 (PD-1) inhibitory receptor with therapeutic antibodies against either the ligand (PD-L1) or PD-1 itself has proven to be an effective treatment modality for multiple cancers. Contrasting with antibodies, small molecules could demonstrate i...

Descripción completa

Detalles Bibliográficos
Autores principales: Koblish, Holly K., Wu, Liangxing, Wang, Liang-Chuan S., Liu, Phillip C.C., Wynn, Richard, Rios-Doria, Jonathan, Spitz, Susan, Liu, Hao, Volgina, Alla, Zolotarjova, Nina, Kapilashrami, Kanishk, Behshad, Elham, Covington, Maryanne, Yang, Yan-ou, Li, Jingwei, Diamond, Sharon, Soloviev, Maxim, O'Hayer, Kevin, Rubin, Stephen, Kanellopoulou, Chrysi, Yang, Gengjie, Rupar, Mark, DiMatteo, Darlise, Lin, Luping, Stevens, Christina, Zhang, Yue, Thekkat, Pramod, Geschwindt, Ryan, Marando, Cindy, Yeleswaram, Swamy, Jackson, Jeff, Scherle, Peggy, Huber, Reid, Yao, Wenqing, Hollis, Gregory
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Research 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394386/
https://www.ncbi.nlm.nih.gov/pubmed/35254416
http://dx.doi.org/10.1158/2159-8290.CD-21-1156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394386/
https://www.ncbi.nlm.nih.gov/pubmed/35254416
http://dx.doi.org/10.1158/2159-8290.CD-21-1156

Ejemplares similares